Healx Logo

Rare Treatment Accelerator

We believe in long-term collaborations, in which everyone brings expertise and resources to create the best chances to quickly drive repurposed treatments to rare disease patients

Registration is now open

Register

A rare opportunity

Our Rare Treatment Accelerator provides a collaborative way for us to work alongside selected patient groups to discover new treatments for rare disease patients. The programme is designed to allow the joint team of experts to cooperatively review the shared data and other resources, run it through our Healnet AI platform, and review and validate the predictions for clinical trials. We – Healx – expect to fund the in silico to clinical trial phase, which we hope to complete within 24 months.

Register
Icon
Vector Dr. Bruce Bloom

Patient groups, patients and carers have insights, resources and relationships that can multiply the speed and value of our AI therapy discovery. We need each other to make quick progress for rare disease patients.

Dr. Bruce Bloom
Founder of Cures Within Reach, Healx Chief Collaboration Officer
Vector Michael Tranfaglia

The Healx partnership has been nothing short of amazing. In less than two years together, we were able to deliver decades-worth of drug discovery, and now we’re taking those discoveries to the clinic.

Michael Tranfaglia
Medical Director, Treasurer, Co-Founder, FRAXA Research Foundation
Vector Dr Rick Thompson

Healx combine a deep knowledge of drug repurposing with a passionate desire to deliver real change to rare disease patients.

Dr Rick Thompson
Head of Research, Find a Cure
Vector Cesare Spadoni

Healx changed my perception of what's possible in drug development.

Cesare Spadoni
Founder and Chairman of the Board, aPODD Foundation

How to apply

Please click the button below to register. Once we’ve received your request, we’ll send you the application form to complete – and ask that you return it to accelerate@healx.io before 10 January 2020.

Along with the application form, we’ll send you a guidance document to help you complete your application. This will also tell you more about eligibility and our judging criteria.

We’ve included a list of FAQs below but if there’s anything we haven’t answered, please get in touch with us at accelerate@healx.io

Register
Icon

Faster together

If your application is successful, we’ll start by working together to define a treatment discovery strategy. From there we expect the project to move along the following timeline.

Icon Icon
Icon

Key dates

Icon
Icon

Who's eligible?

The Rare Treatment Accelerator is open to patient groups worldwide that focus on rare diseases. Umbrella organisations that support more than one rare disease can help by encouraging their supported patient groups to participate. All patient groups must represent patients and be registered as a charity or foundation.

Icon

And who's not?

For the time being, we won’t be able to accept applications from common disease patient groups – we’re only considering groups that represent diseases with a prevalence of less than 5 in 10,000. We encourage rare disease patients and their carers to participate, although they’ll have to apply through a patient group.

Icon

Industry partner?

Although the Rare Treatment Accelerator is not open to industry partners, we pursue licensing and co-development partnerships with industry to translate new treatments towards the clinic.

Learn more
Vector

Icon FAQs

The Rare Treatment Accelerator panel is made up of our senior leadership team (to include our CSO and COO), who collectively hold over 65 years of drug discovery expertise in industry.

The application is designed to give us a comprehensive look at your organisation, rare disease of interest, network and other resources. For a collaboration to have the greatest potential, we’ll need sufficient, relevant data to apply in our AI platform, and we’ll have to be able to use multiple drug-matching methods so we can cross-validate and get more robust drug predictions.

We’re not setting a limit to the number of partnerships, although we may have to stagger them to fit everyone’s schedules.

Although different regions have their own definitions of a rare disease, we broadly define it as any condition that affects less than 1 person in 2,000 (5 in 10,000) and whose symptoms have unmet medical needs.

For the application, we’re asking you to submit only non-confidential data. If and when we agree on a collaboration, there may be a mutual exchange of confidential information, at which point we (both parties) will sign the necessary confidentiality agreements so that we can quickly start working towards finding treatments for the patients.

We’re eager to partner with as many collaborators as possible around individual rare diseases. We would ask collaboration groups to designate a lead charity to submit the application and, if the disease is selected, to contract with us.

Unfortunately, the Rare Treatment Accelerator programme isn’t open to industry yet, although we do collaborate with companies interested in one of our industry partnerships. If you think you or any companies you know might be interested in this, please contact our business development team at partnerships@healx.io to find out more.

This depends on the stage of the project we’re in, but to put things simply, this partnership comes at no cost to the patient group, except for the time it takes you to help us work with your resources. We’re looking for expertise, information, advice, and perhaps most importantly, we’re looking for engaged and collaborative partners.

The Rare Treatment Accelerator is open to rare disease-specific patient groups and umbrella organisations worldwide. For more information on whether or not you qualify, we recommend you read the guidance document for applicants available when you register for the programme. You can register for the Rare Treatment Accelerator here.

We’ve already used our technology platform to help other patient groups successfully identify repurposed candidate drugs and get them ready for clinical trials within 24 months of starting a project. We want to use our AI platform Healnet to accelerate and de-risk the drug discovery process with additional patient groups, so we can get new treatments faster and cheaper to those who need it most.

We’re open to working with patient groups worldwide.

There is no cost to apply, and the partnership will be at no cost to selected patient groups.

Umbrella charities can help by sharing the Rare Treatment Accelerator Program with the specific rare disease patient charity groups they represent. If an umbrella charity wants to apply on its own, it will have to submit a separate application for each disease.

Unfortunately, the Rare Treatment Accelerator is aimed at registered patient groups and/or umbrella organisations. The best way for patients and carers to participate is through one of these organisations. If you’re a rare disease patient or carer and need support in organising or contacting a disease-specific charity, please reach out to a rare disease umbrella group such as Findacure, Global Genes, Canadian Organization of Rare Diseases, NORD or Rare Disease Foundation Canada.

If you’re having trouble completing the application by 10 January 2020, please feel free to contact us at accelerate@healx.io and someone from our team will be in touch with you to help.

If you’re having trouble submitting online, please contact us at accelerate@healx.io and someone from our team will be in touch with you to help.

Our technology

Our AI leverages its unique combination of algorithms to predict and de-risk novel connections in biomedical data, and move the most promising ones towards the clinic.

About Healx

We’re a next-generation team of drug hunters, AI engineers and bioinformaticians, all working together to accelerate the discovery of new treatments for rare diseases.